Dechert advised Abivax on its successful €49.2 million financing with top U.S. and European biotech specialist investors. The financing was underwritten by new and existing biotech investors based in the U.S. and Europe and led by TCGX, with participation from Venrock Healthcare Capital Partners, Deep Track Capital, Sofinnova Partners, Invus and Truffle Capital.
Company Information
Company
Abivax
Location
Rue De La Baume
Paris, Ile-de-France, France
About
Abivax is developing therapies that modulate the body’s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, viral diseases and liver cancer. Abivax is based on innovative research driven by the idea of modulating the body’s natural immune system mechanisms to treat diseases.
Fundz sees it the moment Abivax raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
ParisBiotechnologyHealth CareMedicalTherapeuticsPharmaceuticalConsultingLegalBiopharma